Last reviewed · How we verify
Generic travoprost
Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Generic travoprost |
|---|---|
| Also known as | Travoprost |
| Sponsor | Université de Sherbrooke |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost mimics the action of naturally occurring prostaglandins by activating FP receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia (redness)
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE4)
- Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |